Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Consulting agrmnt
Appointed director
Quarterly results
Inv. presentation
Director departure
EXICURE, INC. (XCUR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 8-K Quarterly results
Docs: "Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update"
07/14/2023 8-K Quarterly results
11/14/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
11/19/2021 8-K Quarterly results
Docs: "Exicure, Inc. Reports Third Quarter 2021 Financial Results and Corporate Progress"
11/12/2020 8-K Quarterly results
Docs: "Exicure, Inc. Reports Third Quarter 2020 Financial Results and Corporate Progress"
08/12/2020 8-K Quarterly results
05/14/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "Exicure Reports Third Quarter 2019 Financial Results and Recent Developments CHICAGO & CAMBRIDGE, Mass. - November 7, 2019 - Exicure, Inc. , a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid technology, today reported financial results for the third quarter ended September 30, 2019 and provided an update on corporate progress. “Throughout the third quarter we have continued to execute against the strategic goals we set early in the year,” said Dr. David Giljohann, Exicure’s chief executive officer. “Our immuno-oncology clinical trial is progressing as anticipated, while we continue to lay the groundwork for expanding our SNA platform in neurology. This scientific progress has been matched with expanded financial resources arising from our recent $63...."
08/08/2019 8-K Quarterly results
Docs: "Exicure Reports Second Quarter 2019 Financial Results and Recent Developments CHICAGO & CAMBRIDGE, Mass. – August 8, 2019 – Exicure, Inc. , a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, today reported financial results for the second quarter ended June 30, 2019 and provided an update on corporate progress. “The first half of 2019 continued to bring advancements across our pipeline,” said Dr. David Giljohann, Exicure’s chief executive officer. “We are extremely pleased with the strong progress in both our neurology and oncology franchises, while we simultaneously strengthened our board leadership and balance sheet. Our non-human primate data confirmed our enthusiasm for neurological applications of our SNA platform. Our recent $63.3 mi..."
05/08/2019 8-K Quarterly results
Docs: "Exicure, Inc. Reports First Quarter 2019 Financial Results and Reviews Corporate Progress CHICAGO, IL. and CAMBRIDGE, MA. - May 8, 2019 - Exicure, Inc. , a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, today reported financial results for the first quarter ended March 31, 2019 and provided an update on corporate progress. “Exicure continues to drive our SNA technology into the clinic and expand our therapeutic areas of interest. In the first quarter of 2019, we opened four clinical sites and began enrolling patients in the Phase 1b/2 trial of AST-008 for patients with advanced or metastatic solid tumors including, Merkel cell carcinoma, melanoma, squamous carcinoma and squamous cell carcinoma of the head and neck,” said Dr. David Giljoh..."
11/06/2018 8-K Quarterly results
Docs: "Exicure, Inc. Provides Update on Corporate Progress and Third Quarter 2018 Financial Results SKOKIE, Ill. - November 6, 2018 - Exicure, Inc. , the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional, spherical nucleic acid constructs, today reported financial results for the third quarter ended September 30, 2018, and provided an update on corporate progress. “During the quarter, we made progress in our clinical program in immuno-oncology while expanding our preclinical data in a growing number of disease models,” said Dr. David Giljohann, Chief Executive Officer of Exicure. “The FDA informed us that our Phase1b/2 clinical trial in immuno-oncology may proceed. We also completed patient dosing in a Phase1 trial for Exicure’s lead anti-inflammatory compound. Ad..."
08/06/2018 8-K Quarterly results
Docs: "Exicure, Inc. Provides Update on Corporate Progress and Second Quarter 2018 Financial Results"
11/14/2017 8-K Quarterly results
Docs: "Exicure, Inc. Reports Third Quarter 2017 Financial Results and Provides Business Update SKOKIE, Ill.—November 14, 2017—Exicure, Inc., a Delaware corporation , the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional Spherical Nucleic Acid constructs, today reported its financial results for the third quarter ended September 30, 2017. “The third quarter was a transformational period for the Company. We continued to advance two SNA drug candidates toward their Phase 1 clinical trials and began our life as a public company,” said David Giljohann, Chief Executive Officer of the Company. “We also strengthened our financial position with an initial private placement of approximately $20 million in gross proceeds, followed in the fourth quarter with two subsequent cl..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy